Genetic or pharmacological inhibition of TXNIP by siRNA or icariin significantly mitigated PA-induced insulin resistance (Figures 1–3), further backing up previous speculation that TXNIP in skeletal muscle is a promising therapeutic target for prevention and treatment of insulin resistance and diabetes. The gene discussed is TXNIP; the disease is Insulin resistance.